By Dominic Tyer (European Pharmaceutical Review)2025-08-20T11:27:31
The drug is the first treatment for desmoid tumours to be approved in the region.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-30T14:00:00Z 2026-06-30T15:00:00Z
Sponsored by BioRad
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-05-30T09:22:00
Sponsored by Lonza QC Testing Solutions
2026-05-27T13:00:00 2026-05-27T14:00:00
Sponsored by TA Instruments
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
2026-02-25T15:00:00
Sponsored by Particle Measuring Systems
2025-06-03T13:35:00
Sponsored by bioMérieux, By European Pharmaceutical Review
Site powered by Webvision Cloud